Literature DB >> 28197653

Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.

A Botticella1, G Defraene2, K Nackaerts3, C Deroose4, J Coolen5, P Nafteux6, B Vanstraelen7, S Joosten8, L A W Michiels8, S Peeters2,7, D De Ruysscher2,9.   

Abstract

BACKGROUND: After lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation.
MATERIALS AND METHODS: In all, 12 consecutive stage I-IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured. Two sets of planning target volumes (PTV) were generated for each patient: (1) a "selective" PTV (S-PTV), originating from a 5-mm isotropic expansion from the GTV and (2) an "elective" PTV (E-PTV), originating from a 5-mm isotropic expansion from the whole ipsilateral pleural space. Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a "selective" pleural irradiation plan (SPI plan) and an "elective" pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]).
RESULTS: In the SPI plans, the average median dose to the S‑PTV was 53.6 Gy (range 41-63.6 Gy). In 4 of 12 patients, it was possible to escalate the dose to the S‑PTV to >58 Gy. In the EPI plans, the average median doses to the E‑PTV and to the S‑PTV were 48.6 Gy (range 38.5-58.7) and 49 Gy (range 38.6-59.5 Gy), respectively. No significant dose escalation was achievable.
CONCLUSION: The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.

Entities:  

Keywords:  Elective pleural irradiation; Lung-sparing VMAT; Malignant pleural mesothelioma; Nonsurgical treatments; Selective pleural irradiation

Mesh:

Year:  2017        PMID: 28197653     DOI: 10.1007/s00066-017-1108-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

Review 1.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

2.  Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.

Authors:  Emilio Minatel; Marco Trovo; Jerry Polesel; Tania Baresic; Alessandra Bearz; Giovanni Franchin; Carlo Gobitti; Imad Abu Rumeileh; Annalisa Drigo; Paolo Fontana; Vittore Pagan; Mauro G Trovo
Journal:  Lung Cancer       Date:  2013-10-27       Impact factor: 5.705

3.  Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study.

Authors:  Angela Botticella; Gilles Defraene; Kristiaan Nackaerts; Christophe M Deroose; Johan Coolen; Philippe Nafteux; Stephanie Peeters; Umberto Ricardi; Dirk De Ruysscher
Journal:  Acta Oncol       Date:  2016-10-12       Impact factor: 4.089

Review 4.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

5.  Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.

Authors:  William W Chance; David C Rice; Pamela K Allen; Anne S Tsao; Hiral P Fontanilla; Zhongxing Liao; Joe Y Chang; Chad Tang; Hubert Y Pan; James W Welsh; Reza J Mehran; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-25       Impact factor: 7.038

6.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

7.  Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.

Authors:  Malcolm Feigen; Sze Ting Lee; Catherine Lawford; Katheryn Churcher; Eddy Zupan; Andrew M Scott; Chris Hamilton
Journal:  J Med Imaging Radiat Oncol       Date:  2011-06       Impact factor: 1.735

8.  Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.

Authors:  Emilio Minatel; Marco Trovo; Jerry Polesel; Imad Abu Rumeileh; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Annalisa Drigo; Andrea Dassie; Vittore Pagan; Mauro G Trovo
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

9.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

10.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

View more
  3 in total

Review 1.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

2.  Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.

Authors:  Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder
Journal:  Strahlenther Onkol       Date:  2019-03-26       Impact factor: 3.621

3.  Dosimetric evaluation of helical tomotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma: a planning study for dose escalation.

Authors:  Fu-Li Zhang; Na Lu; Hua-Yong Jiang; Dian-Dian Chen; Ya-Di Wang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.